Compare Cipla with Aurobindo Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CIPLA vs AUROBINDO PHARMA - Comparison Results

Rs 100 invested in...

Loading...
DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CIPLA AUROBINDO PHARMA CIPLA/
AUROBINDO PHARMA
 
P/E (TTM) x 30.0 11.4 262.0% View Chart
P/BV x 4.2 1.4 300.3% View Chart
Dividend Yield % 0.5 0.8 68.7%  

Financials

 CIPLA   AUROBINDO PHARMA
EQUITY SHARE DATA
    CIPLA
Mar-21
AUROBINDO PHARMA
Mar-21
CIPLA/
AUROBINDO PHARMA
5-Yr Chart
Click to enlarge
High Rs8791,023 85.9%   
Low Rs411333 123.2%   
Sales per share (Unadj.) Rs237.6422.8 56.2%  
Earnings per share (Unadj.) Rs29.892.0 32.4%  
Cash flow per share (Unadj.) Rs43.0110.0 39.1%  
Dividends per share (Unadj.) Rs5.004.00 125.0%  
Avg Dividend yield %0.80.6 131.5%  
Book value per share (Unadj.) Rs226.7374.3 60.6%  
Shares outstanding (eoy) m806.46585.94 137.6%   
Bonus / Rights / Conversions 00-  
Price / Sales ratio x2.71.6 169.1%   
Avg P/E ratio x21.67.4 293.6%  
P/CF ratio (eoy) x15.06.2 243.0%  
Price / Book Value ratio x2.81.8 156.9%  
Dividend payout %16.84.3 386.1%   
Avg Mkt Cap Rs m519,826397,398 130.8%   
No. of employees `000NANA-   
Total wages/salary Rs m32,51835,350 92.0%   
Avg. sales/employee Rs Th00-  
Avg. wages/employee Rs Th00-  
Avg. net profit/employee Rs Th00-  
INCOME DATA
Net Sales Rs m191,596247,746 77.3%  
Other income Rs m2,6983,809 70.8%   
Total revenues Rs m194,294251,555 77.2%   
Gross profit Rs m42,48781,480 52.1%  
Depreciation Rs m10,67710,554 101.2%   
Interest Rs m1,607745 215.7%   
Profit before tax Rs m32,90173,990 44.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m8,88820,098 44.2%   
Profit after tax Rs m24,01353,892 44.6%  
Gross profit margin %22.232.9 67.4%  
Effective tax rate %27.027.2 99.4%   
Net profit margin %12.521.8 57.6%  
BALANCE SHEET DATA
Current assets Rs m132,095198,235 66.6%   
Current liabilities Rs m45,916106,652 43.1%   
Net working cap to sales %45.037.0 121.7%  
Current ratio x2.91.9 154.8%  
Inventory Days Days6819 352.6%  
Debtors Days Days752 12.7%  
Net fixed assets Rs m116,277135,778 85.6%   
Share capital Rs m1,613586 275.3%   
"Free" reserves Rs m181,232218,713 82.9%   
Net worth Rs m182,844219,299 83.4%   
Long term debt Rs m12,0281,684 714.2%   
Total assets Rs m248,372334,013 74.4%  
Interest coverage x21.5100.3 21.4%   
Debt to equity ratio x0.10 856.6%  
Sales to assets ratio x0.80.7 104.0%   
Return on assets %10.316.4 63.1%  
Return on equity %13.124.6 53.4%  
Return on capital %17.733.8 52.4%  
Exports to sales %31.353.8 58.2%   
Imports to sales %10.916.4 66.6%   
Exports (fob) Rs m59,951133,248 45.0%   
Imports (cif) Rs m20,91140,615 51.5%   
Fx inflow Rs m68,051133,248 51.1%   
Fx outflow Rs m20,91144,946 46.5%   
Net fx Rs m47,14088,302 53.4%   
CASH FLOW
From Operations Rs m37,55233,289 112.8%  
From Investments Rs m-23,8725,987 -398.7%  
From Financial Activity Rs m-13,299-13,648 97.4%  
Net Cashflow Rs m50925,831 2.0%  

Share Holding

Indian Promoters % 13.5 48.8 27.7%  
Foreign collaborators % 20.1 3.1 656.0%  
Indian inst/Mut Fund % 48.6 38.3 127.0%  
FIIs % 26.6 20.8 127.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 66.4 48.2 137.8%  
Shareholders   418,584 338,639 123.6%  
Pledged promoter(s) holding % 0.0 14.9 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CIPLA With:   SUN PHARMA    LUPIN    DR. REDDYS LAB    ZYDUS LIFESCIENCES    PIRAMAL ENTERPRISES    

Yellow Ad

Advertisement

Revealed: The 5-Minute Blueprint for Potentially Becoming a One Stock Crorepati

At our One Stock Crorepati mega summit, Richa revealed the 5-minute blueprint for potentially becoming a One Stock Crorepati.

Richa also revealed the 3 traits of what she calls a potential crorepati stock.

Plus...she also revealed details of a tiny company that has all these 3 traits.

You too had signed-up for Richa's summit. But you missed it for some reason.

No worries. You can still watch the special replay of the summit to get all these details.

Learn more



Today's Market

Sensex Ends 111 Points Lower, Nifty Holds 15,750; ONGC, Reliance Crash, while ITC & Bajaj Twins Gain 4%(Closing)

After opening the day deep in the red, Indian share markets slowly recovered most of their losses and ended on a flat note.

Related Views on News

Cipla vs Sun Pharma: Which Pharma Stock is Better? (Views On News)

Apr 13, 2022

The pandemic has opened up new opportunities for the Indian pharmaceutical sector. Which company is set to benefit from it?

5 Stocks to Watch Out for Amid the Omicron Outbreak (Views On News)

Dec 3, 2021

As the new variant of Covid-19 emerges, keep an eye on these stocks.

5 Takeaways from Sun Pharma's Q4 Results (Views On News)

May 30, 2022

It came as a surprise to everyone when Sun Pharma reported a consolidated net loss in Q4 instead of a profit.

Why Divi's Lab Share Price is Falling (Views On News)

May 24, 2022

Here's why Divi's Lab's stock fell over 10% in two days.

Divi's Lab Net Profit Rises 78%. Company Declares 1,500% Dividend (Views On News)

May 23, 2022

For full year, profit figures stood at Rs 29.6 bn as against Rs 19.8 bn for the previous year, reflecting a growth of 49%.

More Views on News

Most Popular

The One Smallcap Stock I'll Recommend Now(Profit Hunter)

Jun 21, 2022

This aspect of investing has a very high weightage on your overall returns, but often gets ignored when winning stories are written.

Wait! Don't Buy the Smallcap 'Dip' Just Yet(Profit Hunter)

Jun 20, 2022

Why this may not be the best time to buy smallcaps.

5 Consistent Compounding Stocks Available at Discount. Time to Buy?(Views On News)

Jun 22, 2022

The good side of a market correction? Investors get consistent compounding stocks at a discount.

Looking for Value Stocks Amid Volatile Times? Consider These 5 Stocks(Views On News)

Jun 20, 2022

These value stocks have the potential to deliver good returns in the long run. Watch out for them.

Why Crude Oil Price is Falling(Views On News)

Jun 25, 2022

Global markets have become volatile, sending chills through the crude oil market.

More

Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

CIPLA SHARE PRICE


Jul 1, 2022 (Close)

TRACK CIPLA

CIPLA - KAMRON LABORATORIES COMPARISON

COMPARE CIPLA WITH

MARKET STATS